Discontinued — last reported Q1 '22
Equity securities
Vertex Pharmaceuticals Equity securities decreased by 66.3% to $9.40M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 71.9%, from $33.40M to $9.40M. Over 4 years (FY 2020 to FY 2024), Equity securities shows a downward trend with a -34.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase reflects positive market performance of the underlying investments or additional capital deployment into equities.
Detailed definition
This represents the fair market value of the company's investment portfolio consisting of equity securities in other ent...
Peer comparison
Standard for companies with large corporate venture arms or significant treasury investment portfolios.
ins_equity_securitiesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $154.10M | $218.76M | $230.90M | $155.30M | $71.10M | $122.80M | $116.80M | $148.10M | $52.60M | $46.40M | $46.00M | $43.40M | $30.60M | $33.40M | $36.60M | $21.60M | $27.90M | $9.40M |
| QoQ Change | — | +42.0% | +5.5% | -32.7% | -54.2% | +72.7% | -4.9% | +26.8% | -64.5% | -11.8% | -0.9% | -5.7% | -29.5% | +9.2% | +9.6% | -41.0% | +29.2% | -66.3% |
| YoY Change | — | — | — | — | -53.9% | -43.9% | -49.4% | -4.6% | -26.0% | -62.2% | -60.6% | -70.7% | -41.8% | -28.0% | -20.4% | -50.2% | -8.8% | -71.9% |
Equity securities at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's equity securities?
- Vertex Pharmaceuticals (VRTX) reported equity securities of $9.40M in Q3 2025.
- How has Vertex Pharmaceuticals's equity securities changed year-over-year?
- Vertex Pharmaceuticals's equity securities decreased by 71.9% year-over-year, from $33.40M to $9.40M.
- What is the long-term trend for Vertex Pharmaceuticals's equity securities?
- Over 4 years (2020 to 2024), Vertex Pharmaceuticals's equity securities has grown at a -34.2% compound annual growth rate (CAGR), from $195.78M to $36.60M.
- What does equity securities mean?
- The current market value of the company's stock investments in other businesses.